RedShiftBio is redefining the possibilities for structural characterization of biomolecules.
RedShiftBio has developed a proprietary life sciences platform combining our Microfluidic Modulation Spectroscopy (MMS) and expertise in high powered quantum cascade lasers that provides ultra-sensitive and ultra-precise measurements of molecular structure. These structural changes affect critical quality attributes governing the safety, efficacy, and stability of biomolecules and their raw materials.
This combination of technologies is available to researchers in our fully-automated Apollo and is backed by a global network of sales, applications, service, and support teams to address all market needs. Led by an experienced management team with a proven track record of success in both large instrumentation companies and commercializing disruptive technologies, RedShiftBio is here to support your research and development goals. Our instruments can be found in the majority of the leading biopharmaceutical companies in the world.
RedShiftBio is backed by Waters Corporation, Illumina Ventures, Technology Venture Partners, and one undisclosed leading life science company.
Our mission is to deploy the power of novel analytical tools in life science research and biopharmaceutical drug development, tackling previously unsolvable problems in structural biology.
To push the boundaries of measurement technology to bring our customers powerful new solutions in biopharmaceutical drug development, process monitoring, manufacturing, and quality control.